Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Stage

Acquired | Acquired

About Angiomics

Angiomics is a research and development company dedicated to improving vascular health. Angiomics tests the efficacy of materials and agents for use as therapies affecting blood vessel growth. It is a seed-stage cancer therapy spinout from Duke University and provides support to industrial, medical, and academic research businesses.

Angiomics Headquarter Location

Indianapolis, Indiana,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Angiomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Angiomics is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.